Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05650190 · ClinicalTrials.gov registry record · NA
Spectacle Lens Visual Acuity Assessments Study
A NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.
- Active
- Registry status
- NA
- Development phase
- 51
- Enrollment target
- 6
- Study locations
NCT05650190: Active NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.
NCT05650190 is a NA study of Myopia and Juvenile Myopia that is active but no longer recruiting, run by SightGlass Vision. The registered enrollment target is 51 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05650190, a NA study of Myopia and Juvenile Myopia, is active but no longer recruiting, sponsored by SightGlass Vision.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.
Primary Outcome
Reading Speed (maximum words per minute)
Conditions Studied
Interventions
- DEVICE Novel spectacle lens design
- DEVICE Spectacle lenses
Study Locations (6)
Florida
- Sabal Eye Care - Longwood
Kansas
- Kannarr Eye Care - Pittsburg
Missouri
- Advanced Eyecare PC - Raytown
New York
- SUNY School of Optometry - New York
Texas
- Vision Optique - Houston
Utah
- William J Bogus, OD, FAAO - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-12-08 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What the registry record for NCT05650190 still lists
NCT05650190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (81% lower).
The record links to 3 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Novel spectacle lens design is the first listed.
NCT05650190 lists 6 locations in 6 states (Florida, Kansas, Missouri).
Frequently Asked Questions
What is clinical trial NCT05650190 about?
NCT05650190 is a clinical study titled "Spectacle Lens Visual Acuity Assessments Study". This is a two-arm parallel group, non-dispensing study. Participants will be existing active CYPRESS Extension (CPRO-1802-002) subjects. Subjects will undergo additional visual performance assessments.
What is the current status of trial NCT05650190?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2022-12-08. Estimated completion is 2026-03-31.
What conditions does trial NCT05650190 study?
This clinical trial studies the following conditions: Myopia, Juvenile Myopia, Myopia Progression.
What interventions are being tested in trial NCT05650190?
The interventions under investigation include: Novel spectacle lens design (DEVICE), Spectacle lenses (DEVICE).
Who is sponsoring clinical trial NCT05650190?
This trial is sponsored by SightGlass Vision, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05650190 being conducted?
This trial has 6 study locations across Florida, Kansas, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05650190's enrollment target sits among peer trials
51 67th of 90 higher than 22 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI